What is Twist Bioscience?
Synthetic DNA and NGS tools company with $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance scale.
- Category
- Synthetic DNA and NGS tools
- Headquarters
- South San Francisco, CA
- Founded
- 2013
- Employees
- 1,000+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: TWST
What is Twist Bioscience?
Twist Bioscience is a Synthetic DNA and NGS tools company headquartered in South San Francisco, CA. As of June 2026, its clearest scale signal is $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance.
Twist Bioscience operates a synthetic DNA manufacturing platform serving DNA synthesis, protein engineering, NGS sample prep, antibody discovery, and biopharma workflows. Its core customer set includes biopharma companies, diagnostics developers, academic labs, industrial biotech companies, synthetic biology teams, and NGS labs, and its public product surface includes Synthetic genes, Oligo pools, NGS target enrichment, Twist Express Genes, Antibody discovery. The current scale signal is $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Twist Bioscience offer?
Twist Bioscience offers Synthetic genes, Oligo pools, NGS target enrichment, Twist Express Genes and related healthcare workflows.
- Synthetic genes· Core product
- Oligo pools· Core product
- NGS target enrichment· Core product
- Twist Express Genes· Workflow
- Antibody discovery· Workflow
- Variant libraries· Workflow
- DNA data storage research· Platform
- Biopharma services· Platform
How does Twist Bioscience make money?
Twist earns product and service revenue from DNA synthesis, protein solutions, and NGS applications, with growth tied to order volume, manufacturing yield, mix, and biopharma demand.
Twist earns product and service revenue from DNA synthesis, protein solutions, and NGS applications, with growth tied to order volume, manufacturing yield, mix, and biopharma demand. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Pricing is product- and quote-based, with online ordering for many oligos and genes and enterprise terms for high-volume synthesis, NGS panels, antibody discovery, and biopharma programs. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Twist Bioscience?
Twist Bioscience is led by Emily M. Leproust, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- Emily M. LeproustCo-founder and Chief Executive OfficerCEO since foundingLeads synthetic DNA platform strategy.
- Adam LaponisChief Financial OfficerCFOOwns finance, guidance, and investor relations.
- Patrick FinnPresident and Chief Operating OfficerOperations leaderLeads operations and commercial execution.
- Paula GreenChief Human Resources OfficerPeople leaderLeads talent and organizational scaling.
How do you contact Twist Bioscience's leadership?
Twist Bioscience publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
investors@twistbioscience.com (official published/company IR contact); personal executive format not verifiedHow much funding has Twist Bioscience raised?
Twist Bioscience is a public company (Nasdaq: TWST), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2013: Founded - Twist is founded to commercialize silicon-based synthetic DNA manufacturing. 2018: IPO - Twist lists on Nasdaq under TWST. 2021: Biopharma expansion - Antibody and protein-solutions offerings broaden the platform. 2025: Fiscal 2025 annual report - Twist files its 2025 annual report and continues revenue growth. 2026: Q2 fiscal 2026 - Twist reports $110.7M of fiscal second-quarter revenue and raises guidance.
As of June 2026, Twist Bioscience's practical funding capacity is best read through Nasdaq: TWST, $110.7M fiscal Q2 2026 revenue; $442M-$447M fiscal 2026 guidance, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Twist Bioscience access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Twist Bioscience get here?
Twist Bioscience grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2013Company foundedTwist begins synthetic DNA manufacturing development.
- 2016Commercial DNA synthesis scalesThe company expands gene and oligo offerings.
- 2018Public listingTwist lists on Nasdaq.
- 2020NGS applications growTarget-enrichment and sample-prep products become a major revenue pillar.
- 2025Growth continuesThe company reports continued fiscal-year growth.
- 2026Guidance raisedTwist raises fiscal 2026 revenue guidance to $442M-$447M.
Who are Twist Bioscience's competitors?
Twist Bioscience competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- Integrated DNA TechnologiesLarge oligonucleotide and synthetic biology products competitor.
- GenScriptGene synthesis, peptide, antibody, and biology-services competitor.
- Eurofins GenomicsSequencing and oligo synthesis service competitor.
- AzentaLife-science sample management and genomics-services competitor.
- SynthegoCRISPR and synthetic biology tools competitor.
- ATUMSynthetic biology, protein engineering, and gene synthesis competitor.
Twist Bioscience — frequently asked questions
